How long does post‑herpetic neuralgia from herpes zoster typically last?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Post-Herpetic Neuralgia from Herpes Zoster

Post-herpetic neuralgia (PHN) typically resolves within 3-12 months in most patients, though a small percentage may experience pain lasting several years, with severity generally diminishing over time.

Natural History and Timeline

The duration of PHN varies significantly based on patient age and initial severity:

Short-Term Course (3-12 Months)

  • At 3 months post-rash: Among patients younger than 60 years, only 1.8% still have PHN, and pain is mild in all cases 1
  • In patients ≥60 years: The risk of PHN at 3 months is higher, but pain is usually mild or moderate; severe pain occurs in only 1.7% of this age group 1
  • At 12 months: No patients reported severe pain, and only 3.3% had mild or moderate pain 1

Long-Term Course (Beyond 1 Year)

  • Of those with pain at 12 months: Seven patients became pain-free within 2-7 years of follow-up 1
  • At 7.6 years: Only five patients reported mild pain and one reported moderate pain 1
  • PHN is defined as pain persisting more than 3 months after the rash has healed, distinguishing it from acute herpes zoster pain 2, 3

Key Prognostic Factors

Age as Primary Determinant

  • Patients <60 years: Very low risk of prolonged PHN with minimal clinical significance 1
  • Patients ≥60 years: Approximately 50% develop PHN, though most cases are mild to moderate 4
  • Overall population: About 15% of all herpes zoster patients develop PHN, but this includes all age groups 4

Clinical Characteristics

  • PHN affects approximately one in five patients overall across all age groups 3
  • The incidence of acute herpes zoster ranges between 3-5 patients per 1000 person-years, with one in four developing PHN 5
  • Sex is not a predictor of PHN duration or severity 1

Important Clinical Caveats

The probability of longstanding pain of clinical importance after herpes zoster is low in unselected primary care populations, particularly those essentially untreated with antiviral drugs 1. However, this represents the natural history without intervention.

Early antiviral treatment within 72 hours of rash onset can reduce both the severity and duration of acute pain, and may decrease the risk of developing PHN 3, 6. The systematic review examining adults with more than 3 months of PHN demonstrates that effective treatments exist (tricyclic antidepressants, gabapentin, pregabalin, topical lidocaine, capsaicin) 7, suggesting that with appropriate management, the functional impact can be mitigated even when pain persists.

Immunocompromised patients (malignancy, systemic steroid use, diabetes) may have different outcomes, though the evidence base for duration in these populations is limited 1.

References

Research

Herpes zoster (shingles) and postherpetic neuralgia.

Mayo Clinic proceedings, 2009

Research

Postherpetic neuralgia: the never-ending challenge.

Pain practice : the official journal of World Institute of Pain, 2005

Research

8. Herpes zoster and post herpetic neuralgia.

Pain practice : the official journal of World Institute of Pain, 2024

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.